Benign prostatic hyperplasia: Evaluation and medical management in primary care

Unnikrishnan, Raman; Almassi, Nima; Fareed, Khaled

doi:10.3949/ccjm.84a.16008

Cited by 39 publications

(29 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Benign outlet obstruction (BOO) caused by benign prostate hyperplasia (BPH) is a common disease that significantly affects quality of life of patients . Medical management is the first step of treatment for moderate lower urinary tract symptoms (LUTS) related to BPH .…”

Section: Introductionmentioning

confidence: 99%

Sexual and functional outcomes of prostate artery embolisation: A prospective long‐term follow‐up, large cohort study

et al. 2019

View full text Add to dashboard Cite

Aim of the study Among minimally invasive procedures for treating benign prostate hyperplasia (BPH) prostate artery embolisation (PAE) is described as safe and effective. Aim of this study is to report our results, focusing on sexual outcomes (erectile and ejaculatory functions sparing) of PAE in patients suffering from bladder outlet obstruction (BOO) secondary to BPH. Methods We prospectively enrolled and submitted to PAE subjects suffering from BOO secondary to BPH. All patients were not suitable for surgery or declined invasive approaches. All subjects were preoperatively and postoperatively (3, 6, 12 and 18 months after) evaluated by urinary flowmetry, post voiding residual volume, prostate volume, serum PSA levels, International Index of Erectile Function, International Prostate Symptom Score and QoL scores. Results PAE was performed in 147 patients (mean age 72.5 y.o.). PAE was technically successful in all patients. The procedure lasted a mean time of 94.3 minutes, with a mean fluoroscopic time of 42.5 minutes. Twelve months follow‐up data were available for all patients, while 126 patients (85%) completed the 18 months follow up. At 12 months follow up, the mean IPSS and QoL scores significantly decreased, and all the objective parameters (mean Qmax, PVR and prostate volume) reported a significant improvement. A total of 130 patients (88.5%) at 12 months reported the antegrade ejaculation preserved, and a slight not significant improvement of IIEF scores. The 18 months after PAE outcomes confirmed the significant improvement of all the variables evaluated (even for PSA values and IIEF scores). No major complications occurred. Conclusions Our results evidence prostate artery embolisation as highly feasible and safe procedure with interesting outcomes. In particular, in our study PAE reported promising results in preserving antegrade ejaculation and erectile function. Our data are in line with the literature, confirming how PAE reduces obstructive symptoms in BPH patients not suitable or refusing standard surgical approaches.

show abstract

Section: Introductionmentioning

confidence: 99%

Sexual and functional outcomes of prostate artery embolisation: A prospective long‐term follow‐up, large cohort study

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Benign Prostatic .Hyperplasia (BPH) is an advancing disease with a peak age of onset at 80 years, recognized by enlargement of the prostate .along with lower urinary tract symptoms (LUTS) [1,2] which could results in chronic UTI, acute urinary retention, renal failure, incontinence of urine & the necessity for BPH related surgery [3,4] . Metabolic syndrome is a cluster of medical conditions which include elevated triglycerides, arterial hypertension, impaired glucose metabolism, low High Density Lipoprotein (HDL) and abdominal obesity [5] .…”

Section: Introductionmentioning

confidence: 99%

Impact of components of metabolic syndrome on the prostatic volume and lower urinary tract symptoms in a sample of patient with benign prostatic hyperplasia in Iraq

Al-Dabbagh¹,

Khudhur²

2019

GJUN

View full text Add to dashboard Cite

Research Article GJUN (2019) 2:17 Impact of components of metabolic syndrome on the prostatic volume and lower urinary tract symptoms in a sample of patient with benign prostatic hyperplasia in Iraq Objective To evaluate the association between the components of metabolic syndrome (MetS) and lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) focusing at their effects on prostatic volume and on the severity of LUTS. Patients & Methods From October 2016 to January 2018, eighty patients presented with LUTS due to the BPH. LUTS were assessed using the international prostatic symptoms score (IPSS) and MetS was defined according to the National Cholesterol Education Program-Adult Treatment Panel III guidelines. Patients were randomly collected into two categories: A (48 patients) had MetS and B (32 patients) without MetS. Results The mean age was 64.3 years, statistically significant variation was identified between the two categories regarding the moderate and severe IPSS, S.PSA, prostatic size and post voiding residue (PVR), the P value (<0.05). The most frequent MetS components were: hypertension in 65/80 patients (81.25%), high fasting glucose in 49/80 patients (61, 25%), and waist circumference elevation in 55/80 patients (68.75%). The association between MetS components, the prostatic volume and severity of LUTS had shown that all MetS components except HDL-cholesterol were significantly correlated with higher prostatic volume (P < 0.05). Also a positive statistically significant association was discovered between each component of MetS and higher IPSS, excepting HDL-cholesterol (P = 0.93) and triglyceride (P = 0.58). Conclusion The results of the present study confirmed that there is a significant relation between the components of metabolic syndrome, the increase in prostatic volume and the severity of LUTS/BPH.

show abstract

“…Benign prostatic hyperplasia (BPH) represents the most commonly diagnosed urological disease in aged men (Unnikrishnan, Almassi, & Fareed, ). Although BPH etiology remains uncertain, prostatic inflammation has been proposed as a crucial part of BPH pathogenesis and progression (Fibbi, Penna, Morelli, et al, ; Nickel, Roehrborn, Castro‐Santamaria, et al, ).…”

Section: Introductionmentioning

confidence: 99%

Compatibility effects of herb pair Phellodendri chinensis cortex and Anemarrhenae rhizoma on benign prostatic hyperplasia using targeted metabolomics

Zhao

Huai

et al. 2018

Biomedical Chromatography

View full text Add to dashboard Cite

Phellodendri chinensis cortex (P. C. cortex) and Anemarrhenae rhizoma (A. rhizoma) herb pair is a core component of traditional Chinese medicines used to treat inflammation and benign prostatic hyperplasia (BPH). The present study was designed to profile the arachidonic acid (AA) metabolomic characteristics in rat plasma and prostate after being treated with P. C. cortex and A. rhizoma as well as their combination. Plasma and prostate samples from sham group, BPH model group, herb pair group and two single herb groups were collected on days 7, 14, 21 and 28. Then, a systemic metabolomic analysis based on UFLC-MS/MS was employed to quantify AA and its cyclooxygenase and lipoxygenase pathway metabolites (15-HETE, 12-HETE, 5-HETE, AA, PGI , PGF , 8-HETE, PGD , PGE and LTB ). The results demonstrated that BPH led a significant increase of 10 biomarkers in plasma and tissue (p < 0.05). The clusters of herb pair group and single herb groups showed a tendency to return to the initial space, and the AA and its metabolites from those groups were differently downregulated to a healthier level, with the combination of single herbs most obvious. The present study demonstrated that P. C. cortex-A. rhizoma herb pair might produce synergistic or complementary compatibility effects on suppressing inflammatory processes occurring in BPH.

show abstract

Benign prostatic hyperplasia: Evaluation and medical management in primary care

Cited by 39 publications

References 49 publications

Sexual and functional outcomes of prostate artery embolisation: A prospective long‐term follow‐up, large cohort study

Sexual and functional outcomes of prostate artery embolisation: A prospective long‐term follow‐up, large cohort study

Impact of components of metabolic syndrome on the prostatic volume and lower urinary tract symptoms in a sample of patient with benign prostatic hyperplasia in Iraq

Compatibility effects of herb pair Phellodendri chinensis cortex and Anemarrhenae rhizoma on benign prostatic hyperplasia using targeted metabolomics

Contact Info

Product

Resources

About